Individualized medicine 2010

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 9, 2010, Pages 2257-2263

  Blum, Hubert E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Array analyses; Disease prognosis; Disease risk; Genome wide association studies; Genomics; Individualized medicine; Metabolomics; MicroRNA; Prediction of therapeutic efficacy; Proteomics; Transcriptomics

Indexed keywords

GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HAPLOTYPE; HUMAN; MUTATION; NEOPLASM; PERSONALIZED MEDICINE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GENE EXPRESSION PROFILING; GENOMICS; HAPLOTYPES; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78649364942     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01155.x     Document Type: Review

References (80)

1. Feero WG, Guttmacher AE, Collins F. Genomic medicine-an updated primer. N Engl J Med. 2010; 362: 2001-11.
2. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409: 860-921.
3. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001; 291: 1304-51.
4. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349: 247-57.
5. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002; 360: 1381-91.
6. Roth AD, Tejpar S, Delorenzi M, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-74.
7. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003; 63: 5738-44.
8. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008; 26: 2690-8.
9. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-74.
10. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008; 359: 1834-6.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-65.
12. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360: 563-72.
13. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med. 2009; 360: 623-5.
14. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17.
15. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-12.
16. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-57.
17. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009; 27: 3117-25.
18. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27: 2231-7.
19. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-17.
20. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010; 375: 1030-47.
21. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801.
22. Suppiah V, Moldovan M, Ahlenstiel G, et al. (2009) IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-4.
23. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-9.
24. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138: 1338-45, e1331-7.
25. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464: 405-8.
26. The International HapMap Project. Nature. 2003; 426: 789-96.
27. A haplotype map of the human genome. Nature. 2005; 437: 1299-320.
28. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008; 118: 1590-605.
29. Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med. 2009; 60: 443-56.
30. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357: 443-53.
31. Rosenzweig A. Scanning the genome for coronary risk. N Engl J Med. 2007; 357: 497-9.
32. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007; 357: 639-47.
33. Dunckley T, Huentelman MJ, Craig DW, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007; 357: 775-88.
34. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357: 851-62.
35. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362: 1082-9.
36. Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008; 299: 53-60.
37. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010; 362: 986-93.
38. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009; 360: 1696-8.
39. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet? N Engl J Med. 2009; 360: 1701-3.
40. Hood L, Heath JR, Phelps ME, et al. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004; 306: 640-3.
41. Caskey CT. Using genetic diagnosis to determine individual therapeutic utility. Annu Rev Med. 2010; 61: 1-15.
42. Alizadeh AA, Eisen MB, Davis RE, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-11.
43. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359: 2313-23.
44. Steidl C, Lee T, Shah SP, et al. Tumorassociated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010. 362: 875-85.
45. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439: 353-7.
46. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 1999-2009.
47. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003; 361: 1590-6.
48. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362: 362-9.
49. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006; 354: 2103-11.
50. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007; 356: 217-26.
51. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007; 356: 294-7.
52. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360: 790-800.
53. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003; 362: 433-9.
54. Chen HY, Yu SL, Chen CH, et al. A fivegene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356: 11-20.
55. Herbst RS, Lippman SM. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med. 2007; 356: 76-8.
56. Fan TW, Lane AN, Higashi RM, et al. Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol. 2009; 87: 83-6.
57. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 2009; 457: 910-4.
58. Maxeiner A, Adkins CB, Zhang Y, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate. 2010. 70: 710-7.
59. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010; 52: 252-7.
60. Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol. 2010; 52: 296-304.
61. Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010; 61: 317-28.
62. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006 44: 798-805.
63. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006; 44: 1012-24.
64. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene. 2006; 25: 3801-9.
65. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007; 45: 42-52.
66. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003; 361: 923-9.
67. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361: 1437-47.
68. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010; 107: 264-9.
69. Yao J, Liang L, Huang S, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010; 51: 846-56.
70. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010; 51: 836-45.
71. Wen H, Yoo SS, Kang J, et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2010; 52: 228-33.
72. Murakami Y, Aly HH, Tajima A, et al. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol. 2009; 50: 453-60.
73. Pietschmann T. Regulation of hepatitis C virus replication by microRNAs. J Hepatol. 2009; 50: 441-4.
74. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology. 2005; 129: 2064-75.
75. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009; 50: 1038-44.
76. Bertini I, Calabro A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009; 8: 170-7.
77. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010; 362: 1890-900.
78. Khor CC, Vannberg FO, Chapman SJ, et al. CISH and susceptibility to infectious diseases. N Engl J Med. 2010; 362: 2092-101.
79. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010; 375: 1525-35.
80. Samani NJ, Tomaszewski M, Schunkert H. The personal genome-the future of personalised medicine? Lancet. 2010; 375: 1497-8.